PRESS RELEASE

Q2 2026 — Press release

Q2 2026PDF · 22 pages583 KB
For immediate release
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
• 2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted
operational growth of 5.7%*
• 2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90
• Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1
Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The
adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint
• Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage
in adults with active psoriatic arthritis, CAPLYTA for the prevention of relapse in schizophrenia, and Dual Energy
THERMOCOOL SMARTTOUCH SF platform; fortifying future with data from RYBREVANT FASPRO in advanced head and
neck cancer, TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma, and OTTAVA in upper
abdominal procedures
New Brunswick, N.J. (July 15, 2026) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026.
“Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our
portfolio and the momentum in our pipeline as we advance transformative treatments that address the world’s toughest health
challenges,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “With raised guidance and
quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for
the first time in our Company’s 140-year history.”
Overall financial results
Q2
($ in Millions, except EPS) 	2026 	2025 	% Change
Reported Sales 	$25,310 	$23,743 	6.6%
Net Earnings 	$5,534 	$5,537 	-0.1%
EPS (diluted) 	$2.27 	$2.29 	-0.9%
Q2
Non-GAAP* ($ in Millions, except EPS) 	2026 	2025 	% Change
Operational Sales1,2 	5.6%
Adjusted Operational Sales1,3 	5.7%
Adjusted Net Earnings1,4 	$7,081 	$6,699 	5.7%
Adjusted EPS (diluted)1,4 	$2.90 	$2.77 	4.7%
Free Cash Flow 5,6 	~$8,700 	$6,214
1 	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 	Excludes the impact of translational currency
3 	Excludes the net impact of acquisitions and divestitures and translational currency
4 	Excludes intangible amortization expense and special items
5 	Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow
from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
6 	Second-quarter YTD 2026 is estimated as of July 15, 2026
Media contact:
media-relations@its.jnj.com
Investor contact:
investor-relations@its.jnj.com

-- 1 of 22 --

Note: values may have been rounded
Regional sales results
Q2 	% Change
($ in Millions) 	2026 	2025 	Reported 	Operational1,2 	Currency
Adjusted
Operational1,3
U.S. 	$14,533 	$13,544 	7.3% 	7.3 	- 	7.4
International 	10,777 	10,199 	5.7 	3.4 	2.3 	3.5
Worldwide 	$25,310 	$23,743 	6.6% 	5.6 	1.0 	5.7
1 	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 	Excludes the impact of translational currency
3 	Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Segment sales results
Q2 	% Change
($ in Millions) 	2026 	2025 	Reported 	Operational1,2 	Currency
Adjusted
Operational1,3
Innovative Medicine 	$16,384 	$15,202 	7.8% 	6.8 	1.0 	6.9
MedTech 	8,926 	8,541 	4.5 	3.6 	0.9 	3.7
Worldwide 	$25,310 	$23,743 	6.6% 	5.6 	1.0 	5.7
1 	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2 	Excludes the impact of translational currency
3 	Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded
Second-Quarter 2026 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 6.8%*, with divestitures negatively impacting growth by 10 basis points.
Growth was primarily driven by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and
Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an
approximate 760 basis points impact) and REMICADE in Immunology, as well as IMBRUVICA and ZYTIGA in Oncology.
MedTech
MedTech worldwide operational sales grew 3.6%*, with net acquisitions and divestitures negatively impacting growth by 10
basis points. Growth was primarily driven by wound closure products and biosurgery products in Surgery, electrophysiology
products and Shockwave in Cardiovascular, contact lenses in Vision, and trauma in Orthopaedics.

-- 2 of 22 --

Full-year 2026 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to
predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related
expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on
various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) 	July 2026 	April 2026
Adjusted Operational Sales1,2
Change vs. Prior Year / Mid-point 6.2% – 6.8% / 6.5% 	5.6% – 6.6% / 6.1%
Operational Sales2 / Mid-point
Change vs. Prior Year / Mid-point
$100.3B – $100.9B / $100.6B
6.5% – 7.1% / 6.8%
$99.7B – $100.7B / $100.2B
5.9% – 6.9% / 6.4%
Estimated Reported Sales3 / Mid-point
Change vs. Prior Year / Mid-point
$100.8B – $101.4B / $101.1B
7.0% – 7.6% / 7.3%
$100.3B – $101.3B / $100.8B
6.5% – 7.5% / 7.0%
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
$11.50 – $11.65 / $11.58
6.6% – 8.0% / 7.3%
$11.30 – $11.50 / $11.40
4.7% – 6.7% / 5.7%
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
$11.60 – $11.75 / $11.68
7.5% – 8.9% / 8.2%
$11.45 – $11.65 / $11.55
6.1% – 8.1% / 7.1%
1 	Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2 	Non-GAAP financial measure; excludes the impact of translational currency
3 	Calculated using Euro Average Rate: July 2026 = $1.15 and April 2026 = $1.17 (Illustrative purposes only)
4 	Non-GAAP financial measure; excludes intangible amortization expense and special items
Note: percentages may have been rounded
Other modeling considerations will be provided on the webcast.
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the
Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual
Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations
section of the company’s website at Investor News, as well as Innovative Medicine Newsroom, MedTech News & Events, and
www.factsabouttalc.com.
Regulatory Johnson & Johnson Announces FDA Approval for the Dual Energy
THERMOCOOL SMARTTOUCH SF Platform1 	Press Release
CHMP recommendation advances Johnson & Johnson’s TECVAYLI
(teclistamab) plus daratumumab as a potential standard of care for
relapsed/refractory multiple myeloma
Press Release
FDA approves label expansion, cementing TREMFYA as the only IL-23
inhibitor proven to help stop further joint damage Press Release
FDA approves CAPLYTA (lumateperone) sNDA with robust new data
supporting reduced risk of relapse in schizophrenia Press Release
Johnson & Johnson Announces CE Mark Approval for the New
ETHICON 4000 Stapler Press Release
FDA grants Priority Review for IMAAVY (nipocalimab-aahu) as the
potential first approved treatment for people living with warm
autoimmune hemolytic anemia (wAIHA)
Press Release

-- 3 of 22 --

Data Releases
Johnson & Johnson presents new IMAAVY (nipocalimab-aahu) data at
European Academy of Neurology (EAN) 2026 Congress reinforcing
sustained disease control in generalized myasthenia gravis
Press Release
New TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj) data demonstrate the strength of
a bispecific combination in earlier-line relapsed or refractory multiple
myeloma
Press Release
IMAAVY (nipocalimab-aahu) demonstrates durable hemoglobin response
and rapid onset of effect in pivotal Phase 2/3 study in warm
autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease
with no FDA-approved therapies
Press Release
Johnson & Johnson late-breaking results show nipocalimab significantly
reduced systemic lupus erythematosus (SLE) disease activity in a Phase
2 study
Press Release
Johnson & Johnson presents new data further reinforcing the role of
nipocalimab in lowering the autoantibodies driving Sjögren's disease Press Release
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) pivotal
data show strong and durable responses in advanced head and neck
cancer where options remain limited
Press Release
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA
(apalutamide) before and after surgery significantly reduces risk of
metastasis or death, breaking a decades-long treatment paradigm
Press Release
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib)
demonstrates prolonged clinical benefit as a first-line treatment for
atypical EGFR-mutated non-small cell lung cancer
Press Release
New TECVAYLI (teclistamab-cqyv) data demonstrate superior
progression-free and overall survival as early as first relapse in multiple
myeloma
Press Release
Johnson & Johnson study shows TREMFYA (guselkumab) is the first
and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing
Crohn's disease
Press Release
Johnson & Johnson investigational co-antibody therapy JNJ-4804
shows potential to raise the bar for clinical efficacy in treating
refractory inflammatory bowel disease
Press Release
Johnson & Johnson Announces Pivotal Clinical Study Results for a New
Soft-Tissue Surgical Robotic System Press Release
CAPLYTA (lumateperone) showed greatest improvement across key
efficacy outcomes among adjunctive MDD treatments in new network
meta-analysis
Press Release
IMAAVY (nipocalimab-aahu) shows over two years of sustained disease
control in a broad population with generalized myasthenia gravis (gMG) Press Release
Product Launch Johnson & Johnson Advances the Standard of Calcium Modification
with Global Launch of Shockwave C2 Aero Coronary IVL Catheter Press Release
Other DePuy Synthes Appoints Christina Zamarro as Chief Financial Officer1
Press Release
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S.
Vision Manufacturing in Jacksonville, Florida Press Release
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an
Advanced Lens Option for Cataract Surgeons and Patients Press Release
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology
Pipeline with Novel Degrader Antibody Conjugate Platform Press Release
DePuy Synthes Announces Agreement to Acquire Miniature
Radiofrequency Tracking Technology Across its Joint Reconstruction
Portfolio
Press Release
DePuy Synthes Enters Exclusive U.S., Canada and Australia Distribution
Agreement for CGBIO’s NOVOSIS Press Release

-- 4 of 22 --

Groundbreaking global survey captures the significant patient burden
experienced with current standard-of-care bladder cancer treatments,
underscoring urgency for continued innovation
Press Release
Johnson & Johnson Appoints Ryan Koors as Vice President, Investor
Relations Press Release
Johnson & Johnson Launches Landmark Head-to-Head Pulsed Field
Ablation Trial in Persistent Atrial Fibrillation Press Release
Johnson & Johnson Showcases CARTO-Powered Innovation, Including
Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS
2026
Press Release
1 	Subsequent to the quarter
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson &
Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations
section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full
spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the
net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted
earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense
and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read
together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-
GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial
schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly
results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of
non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including
adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and
a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at
quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things: future operating and financial performance, product development, and market position and
business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and
uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or

-- 5 of 22 --

changes to applicable laws and regulations; competition, including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans;
the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain;
product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or
government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws
and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and
sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to
successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation.
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent
Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and
“Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com,
or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or
future events or developments.

-- 6 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operations Currency 2026 2025 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 9,979	$ 9,161 8.9 % 8.9 - 18,850	$ 17,253 9.3 % 9.3 -
International 6,405 6,041 6.0 3.6 2.4 12,960 11,822 9.6 3.9 5.7
16,384 15,202 7.8 6.8 1.0 31,810 29,075 9.4 7.1 2.3
MedTech
U.S. 4,554 4,383 3.9 3.9 - 9,013 8,596 4.8 4.8 -
International 4,372 4,158 5.2 3.2 2.0 8,549 7,965 7.3 3.2 4.1
8,926 8,541 4.5 3.6 0.9 17,562 16,561 6.0 4.1 1.9
U.S. 14,533 13,544 7.3 7.3 - 27,863 25,849 7.8 7.8 -
International 10,777 10,199 5.7 3.4 2.3 21,509 19,787 8.7 3.6 5.1
Worldwide 25,310	$ 23,743 6.6 % 5.6 1.0 49,372	$ 45,636 8.2 % 6.0 2.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER SIX MONTHS
Percent Change

-- 7 of 22 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operational Currency 2026 2025 Total Operational Currency
Sales to customers by
geographic area
U.S. 14,533	$ 13,544 7.3 % 7.3 - 27,863	$ 25,849 7.8 % 7.8 -
Europe 5,726 5,387 6.3 3.3 3.0 11,574 10,497 10.3 3.0 7.3
Western Hemisphere excluding U.S. 1,309 1,206 8.5 2.7 5.8 2,602 2,373 9.6 2.6 7.0
Asia-Pacific, Africa 3,742 3,606 3.8 3.9 (0.1) 7,333 6,917 6.0 4.9 1.1
International 10,777 10,199 5.7 3.4 2.3 21,509 19,787 8.7 3.6 5.1
Worldwide 25,310	$ 23,743 6.6 % 5.6 1.0 49,372	$ 45,636 8.2 % 6.0 2.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER SIX MONTHS
Percent Change

-- 8 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 25,310	$ 100.0 23,743	$ 100.0 6.6
Cost of products sold 8,051 31.8 7,628 32.1 5.5
Gross Profit 17,259 68.2 16,115 67.9 7.1
Selling, marketing and administrative expenses 6,432 25.4 5,889 24.8 9.2
Research and development expense 3,653 14.4 3,516 14.8 3.9
Interest (income) expense, net 62 0.2 48 0.2
Other (income) expense, net 331 1.3 107 0.5
Restructuring 34 0.2 64 0.3
Earnings before provision for taxes on income 6,747 26.7 6,491 27.3 3.9
Provision for taxes on income 1,213 4.8 954 4.0 27.1
Net earnings 5,534	$ 21.9 5,537	$ 23.3 (0.1)
Net earnings per share (Diluted) 2.27	$ 2.29	$ (0.9)
Average shares outstanding (Diluted) 2,440.1 2,419.1
Effective tax rate 18.0 % 14.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 8,660	$ 34.2 8,188	$ 34.5 5.8
Net earnings 7,081	$ 28.0 6,699	$ 28.2 5.7
Net earnings per share (Diluted) 2.90	$ 2.77	$ 4.7
Effective tax rate 18.2 % 18.2 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2026 2025

-- 9 of 22 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 49,372	$ 100.0 45,636	$ 100.0 8.2
Cost of products sold 16,157 32.7 14,985 32.8 7.8
Gross Profit 33,215 67.3 30,651 67.2 8.4
Selling, marketing and administrative expenses 12,466 25.3 11,001 24.1 13.3
Research and development expense 7,180 14.5 6,741 14.8 6.5
In-process research and development impairments 36 0.1 - -
Interest (income) expense, net 105 0.2 (80) (0.2)
Other (income) expense, net 625 1.3 (7,214) (15.8)
Restructuring 66 0.1 81 0.2
Earnings before provision for taxes on income 12,737 25.8 20,122 44.1 (36.7)
Provision for taxes on income 1,968 4.0 3,586 7.9 (45.1)
Net earnings 10,769	$ 21.8 16,536	$ 36.2 (34.9)
Net earnings per share (Diluted) 4.41	$ 6.82	$ (35.3)
Average shares outstanding (Diluted) 2,443.9 2,423.3
Effective tax rate 15.5 % 17.8 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 16,481	$ 33.4 16,199	$ 35.5 1.7
Net earnings 13,695	$ 27.7 13,405	$ 29.4 2.2
Net earnings per share (Diluted) 5.60	$ 5.53	$ 1.3
Effective tax rate 16.9 % 17.2 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2026 2025

-- 10 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2026 2025 2026 2025
Net Earnings, after tax- as reported $5,534 $5,537 $10,769 $16,536
Pre-tax Adjustments
Litigation related 267 57 597 (6,909)
Intangible Asset Amortization expense 1,245 1,267 2,492 2,387
Restructuring related 1 276 79 338 134
Orthopaedics separation related 258 - 377 -
Acquisition, integration and divestiture related 80 246 176 378
(Gains)/losses on securities (213) 21 (272) 60
IPR&D impairments - - 36 -
Other - 27 - 27
Tax Adjustments
Tax impact on special item adjustments 2 (368) (321) (792) 994
Tax legislation and other tax related 2 (214) (26) (202)
Adjusted Net Earnings , after tax $7,081 $6,699 $13,695 $13,405
Average shares outstanding (Diluted) 2,440.1 2,419.1 2,443.9 2,423.3
Adjusted net earnings per share (Diluted) $2.90 $2.77 $5.60 $5.53
Operational adjusted net earnings per share (Diluted) $2.86 $5.43
Notes:
1
2
Second Quarter Six Months Ended
In the fiscal second quarter of 2026, the Company commenced a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its
optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site
and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of
2026.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and
optimize select sites across the network. Restructuring expenses of $59 million were recorded in the fiscal second quarter of 2026 ($114 million Q2 2026 YTD) and $29 million in the fiscal second
quarter of 2025 ($29 million Q2 2025 YTD) and primarily include costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and
distribution network arrangements. The restructuring expenses of $17 million in the fiscal second quarter of 2026 ($24 million Q2 2026 YTD) and $50 million in the fiscal second quarter of 2025
($105 million Q2 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 11 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 7.8% 4.5% 6.6%
U.S. 8.9% 3.9% 7.3%
International 6.0% 5.2% 5.7%
WW Currency 1.0 0.9 1.0
U.S. - - -
International 2.4 2.0 2.3
WW Operational 6.8% 3.6% 5.6%
U.S. 8.9% 3.9% 7.3%
International 3.6% 3.2% 3.4%
All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1
U.S. 0.0 0.2 0.1
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.9% 3.7% 5.7%
U.S. 8.9% 4.1% 7.4%
International 3.8% 3.2% 3.5%
Adjusted Operational Sales Growth
SECOND QUARTER 2026 ACTUAL vs. 2025 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 12 of 22 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 9.4% 6.0% 8.2%
U.S. 9.3% 4.8% 7.8%
International 9.6% 7.3% 8.7%
WW Currency 2.3 1.9 2.2
U.S. - - -
International 5.7 4.1 5.1
WW Operational 7.1% 4.1% 6.0%
U.S. 9.3% 4.8% 7.8%
International 3.9% 3.2% 3.6%
Caplyta (0.9) (0.6)
U.S. (1.6) (1.0)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1
U.S. 0.0 0.2 0.1
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.2% 4.2% 5.5%
U.S. 7.7% 5.0% 6.9%
International 4.1% 3.2% 3.7%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2026 ACTUAL vs. 2025 ACTUAL
Segments

-- 13 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
ONCOLOGY
US 4,069	$ 3,385 20.3% 20.3% - 7,684	$ 6,398 20.1% 20.1% -
Intl 3,337 2,928 14.0% 11.2% 2.8% 6,695 5,592 19.7% 13.2% 6.5%
WW 7,406 6,312 17.3% 16.1% 1.2% 14,379 11,990 19.9% 16.9% 3.0%
DARZALEX
US 2,435 2,017 20.7% 20.7% - 4,643 3,846 20.7% 20.7% -
Intl 1,772 1,521 16.4% 13.5% 2.9% 3,528 2,930 20.4% 13.7% 6.7%
WW 4,207 3,539 18.9% 17.6% 1.3% 8,171 6,776 20.6% 17.7% 2.9%
CARVYKTI
US 472 358 31.7% 31.7% - 905 676 33.8% 33.8% -
Intl 185 81 * * * 349 132 * * *
WW 657 439 49.4% 47.7% 1.7% 1,254 808 55.1% 52.1% 3.0%
TECVAYLI
US 186 114 63.9% 63.9% - 313 219 43.1% 43.1% -
Intl 74 52 40.7% 39.2% 1.5% 148 98 51.1% 45.2% 5.9%
WW 260 166 56.5% 56.1% 0.4% 462 317 45.5% 43.7% 1.8%
TALVEY
US 112 82 36.2% 36.2% - 213 150 41.7% 41.7% -
Intl 62 24 * * * 113 42 * * *
WW 174 106 63.3% 62.6% 0.7% 326 192 69.3% 67.2% 2.1%
RYBREVANT / LAZCLUZE
US 190 139 36.8% 36.8% - 365 252 45.0% 45.0% -
Intl 99 41 * * * 181 69 * * *
WW 289 179 60.8% 61.6% (0.8)% 546 320 70.4% 69.9% 0.5%
ERLEADA
US 396 378 4.7% 4.7% - 738 670 10.2% 10.2% -
Intl 599 530 12.9% 9.7% 3.2% 1,206 1,009 19.4% 12.5% 6.9%
WW 995 908 9.5% 7.6% 1.9% 1,944 1,679 15.8% 11.6% 4.2%
IMBRUVICA
US 149 239 (37.6)% (37.6)% - 292 474 (38.4)% (38.4)% -
Intl 449 496 (9.5)% (11.8)% 2.3% 966 970 (0.4)% (6.7)% 6.3%
WW 599 735 (18.6)% (20.2)% 1.6% 1,259 1,444 (12.9)% (17.1)% 4.2%
OTHER ONCOLOGY (3)
US 131 56 * * - 216 110 94.5% 94.5% -
Intl 97 181 (46.5)% (45.7)% (0.8)% 203 341 (40.5)% (41.3)% 0.8%
WW 226 238 (4.6)% (3.9)% (0.7)% 418 452 (7.4)% (8.0)% 0.6%
See footnotes at end of schedule
% Change	% Change

-- 14 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
IMMUNOLOGY
US 2,372	$ 2,505 (5.3)% (5.3)% - 4,227	$ 4,701 (10.1)% (10.1)% -
Intl 1,473 1,489 (1.0)% (3.5)% 2.5% 2,997 2,999 (0.1)% (5.0)% 4.9%
WW 3,844 3,993 (3.7)% (4.6)% 0.9% 7,224 7,700 (6.2)% (8.1)% 1.9%
TREMFYA
US 1,465 796 84.2% 84.2% - 2,507 1,395 79.7% 79.7% -
Intl 581 391 48.7% 44.2% 4.5% 1,147 747 53.6% 45.5% 8.1%
WW 2,046 1,186 72.5% 71.0% 1.5% 3,654 2,142 70.6% 67.8% 2.8%
SIMPONI / SIMPONI ARIA
US 260 305 (14.6)% (14.6)% - 529 597 (11.2)% (11.2)% -
Intl 358 387 (7.3)% (9.5)% 2.2% 736 753 (2.3)% (6.9)% 4.6%
WW 618 690 (10.5)% (11.7)% 1.2% 1,265 1,349 (6.2)% (8.8)% 2.6%
REMICADE
US 215 283 (24.1)% (24.1)% - 484 597 (19.0)% (19.0)% -
US Exports (4) 10 34 (71.0)% (71.0)% - 28 44 (37.1)% (37.1)% -
Intl 112 138 (18.4)% (20.5)% 2.1% 248 281 (11.5)% (15.4)% 3.9%
WW 338 455 (25.8)% (26.4)% 0.6% 760 922 (17.6)% (18.7)% 1.1%
STELARA
US 336 1,078 (68.8)% (68.8)% - 556 2,059 (73.0)% (73.0)% -
Intl 404 575 (29.7)% (31.1)% 1.4% 839 1,219 (31.1)% (34.6)% 3.5%
WW 740 1,653 (55.2)% (55.7)% 0.5% 1,396 3,278 (57.4)% (58.7)% 1.3%
OTHER IMMUNOLOGY
US 85 8 * * - 123 9 * * -
Intl 18 0 * * * 27 0 * * *
WW 104 8 * * * 150 9 * * *
NEUROSCIENCE
US 1,659 1,377 20.5% 20.5% - 3,153 2,345 34.5% 34.5% -
Intl 678 674 0.6% (1.1)% 1.7% 1,359 1,353 0.4% (3.7)% 4.1%
WW 2,337 2,051 14.0% 13.4% 0.6% 4,512 3,698 22.0% 20.5% 1.5%
SPRAVATO
US 514 366 40.7% 40.7% - 920 642 43.4% 43.4% -
Intl 70 50 41.2% 34.7% 6.5% 131 93 41.8% 31.9% 9.9%
WW 584 414 40.8% 40.0% 0.8% 1,052 734 43.2% 42.0% 1.2%
CAPLYTA (5)
US 361 211 70.9% 70.9% - 631 211 * * -
Intl - - - - - - - - - -
WW 361 211 70.9% 70.9% - 631 211 * * -
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 738 732 0.8% 0.8% - 1,496 1,357 10.2% 10.2% -
Intl 278 260 6.6% 5.1% 1.5% 558 537 3.7% (0.1)% 3.8%
WW 1,015 992 2.3% 1.9% 0.4% 2,053 1,895 8.4% 7.3% 1.1%
CONCERTA / Methylphenidate
US 12 24 (48.6)% (48.6)% - 34 62 (45.5)% (45.5)% -
Intl 133 139 (4.2)% (4.8)% 0.6% 248 249 (0.4)% (3.0)% 2.6%
WW 146 164 (10.8)% (11.3)% 0.5% 282 312 (9.5)% (11.5)% 2.0%
OTHER NEUROSCIENCE
US 34 45 (22.9)% (22.9)% - 72 73 (1.1)% (1.1)% -
Intl 198 226 (12.3)% (13.7)% 1.4% 422 474 (10.9)% (15.1)% 4.2%
WW 232 270 (14.0)% (15.2)% 1.2% 494 547 (9.6)% (13.2)% 3.6%
See footnotes at end of schedule
% Change	% Change

-- 15 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
PULMONARY HYPERTENSION (PH)
US 814	$ 799 1.8% 1.8% - 1,645	$ 1,543 6.5% 6.5% -
Intl 329 314 4.9% 3.4% 1.5% 633 595 6.4% 2.3% 4.1%
WW 1,143 1,113 2.6% 2.2% 0.4% 2,278 2,138 6.5% 5.4% 1.1%
UPTRAVI
US 386 382 1.0% 1.0% - 771 747 3.2% 3.2% -
Intl 108 94 15.0% 10.1% 4.9% 206 180 14.7% 7.7% 7.0%
WW 494 476 3.8% 2.8% 1.0% 977 927 5.4% 4.0% 1.4%
OPSUMIT / OPSYNVI
US 416 403 3.2% 3.2% - 849 766 10.9% 10.9% -
Intl 187 180 3.9% 3.6% 0.3% 359 339 6.1% 2.7% 3.4%
WW 602 582 3.4% 3.3% 0.1% 1,208 1,104 9.4% 8.4% 1.0%
OTHER PULMONARY HYPERTENSION
US 13 16 (16.9)% (16.9)% - 25 31 (19.0)% (19.0)% -
Intl 34 40 (14.3)% (12.7)% (1.6)% 68 77 (11.5)% (12.3)% 0.8%
WW 47 55 (15.0)% (13.9)% (1.1)% 93 107 (13.6)% (14.2)% 0.6%
INFECTIOUS DISEASES (ID)
US 300 320 (6.3)% (6.3)% - 642 635 1.1% 1.1% -
Intl 463 484 (4.1)% (6.2)% 2.1% 1,010 971 4.1% (2.5)% 6.6%
WW 763 803 (5.0)% (6.3)% 1.3% 1,652 1,605 2.9% (1.1)% 4.0%
EDURANT / rilpivirine
US 3 6 (49.6)% (49.6)% - 10 14 (29.3)% (29.3)% -
Intl 347 354 (1.9)% (3.8)% 1.9% 749 704 6.4% (0.3)% 6.7%
WW 350 360 (2.7)% (4.6)% 1.9% 759 718 5.7% (0.9)% 6.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 296 312 (5.1)% (5.1)% - 630 617 2.1% 2.1% -
Intl 76 85 (10.4)% (12.8)% 2.4% 185 183 1.2% (5.6)% 6.8%
WW 372 396 (6.3)% (6.8)% 0.5% 815 799 1.9% 0.4% 1.5%
OTHER INFECTIOUS DISEASES
US 1 2 (47.9)% (47.9)% - 2 4 (51.6)% (51.6)% -
Intl 40 45 (9.6)% (12.8)% 3.2% 76 84 (9.0)% (13.7)% 4.7%
WW 41 47 (11.6)% (14.6)% 3.0% 78 88 (11.1)% (15.5)% 4.4%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US 765 776 (1.3)% (1.3)% - 1,499 1,631 (8.1)% (8.1)% -
Intl 124 154 (19.4)% (21.5)% 2.1% 266 312 (14.8)% (19.5)% 4.7%
WW 889 930 (4.3)% (4.7)% 0.4% 1,765 1,943 (9.2)% (9.9)% 0.7%
XARELTO
US 664 621 7.1% 7.1% - 1,306 1,311 (0.3)% (0.3)% -
Intl - - - - - - - - - -
WW 664 621 7.1% 7.1% - 1,306 1,311 (0.3)% (0.3)% -
OTHER
US 101 155 (35.0)% (35.0)% - 192 320 (39.9)% (39.9)% -
Intl 124 154 (19.4)% (21.5)% 2.1% 266 312 (14.8)% (19.5)% 4.7%
WW 225 309 (27.2)% (28.3)% 1.1% 458 632 (27.5)% (29.8)% 2.3%
TOTAL PH, ID, CVM
US 1,878 1,895 (0.9)% (0.9)% - 3,785 3,809 (0.6)% (0.6)% -
Intl 916 952 (3.6)% (5.5)% 1.9% 1,909 1,878 1.7% (3.8)% 5.5%
WW 2,795 2,846 (1.8)% (2.4)% 0.6% 5,694 5,686 0.1% (1.7)% 1.8%
TOTAL INNOVATIVE MEDICINE
US 9,979 9,161 8.9% 8.9% - 18,850 17,253 9.3% 9.3% -
Intl 6,405 6,041 6.0% 3.6% 2.4% 12,960 11,822 9.6% 3.9% 5.7%
WW 16,384	$ 15,202 7.8% 6.8% 1.0% 31,810	$ 29,075 9.4% 7.1% 2.3%
See footnotes at end of schedule
% Change	% Change

-- 16 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,426	$ 1,364 4.5% 4.5% - 2,825	$ 2,625 7.6% 7.6% -
Intl 978 948 3.2% 1.1% 2.1% 1,956 1,790 9.3% 5.2% 4.1%
WW 2,404 2,313 4.0% 3.1% 0.9% 4,781 4,416 8.3% 6.6% 1.7%
ELECTROPHYSIOLOGY
US 783 741 5.8% 5.8% - 1,519 1,425 6.6% 6.6% -
Intl 749 728 2.9% 0.4% 2.5% 1,502 1,366 10.0% 5.6% 4.4%
WW 1,533 1,468 4.4% 3.1% 1.3% 3,022 2,791 8.3% 6.2% 2.1%
ABIOMED
US 342 360 (4.8)% (4.8)% - 731 699 4.6% 4.6% -
Intl 97 89 9.5% 9.2% 0.3% 197 170 16.1% 11.4% 4.7%
WW 440 448 (2.0)% (2.0)% 0.0% 928 868 6.8% 5.9% 0.9%
SHOCKWAVE
US 268 233 14.6% 14.6% - 510 439 16.1% 16.1% -
Intl 67 58 14.5% 15.4% (0.9)% 130 110 17.7% 17.2% 0.5%
WW 335 292 14.6% 14.7% (0.1)% 640 550 16.4% 16.3% 0.1%
OTHER CARDIOVASCULAR
US 33 31 5.5% 5.5% - 65 63 3.1% 3.1% -
Intl 65 72 (10.5)% (13.2)% 2.7% 127 144 (11.9)% (15.3)% 3.4%
WW 98 104 (5.7)% (7.5)% 1.8% 192 207 (7.4)% (9.7)% 2.3%
SURGERY
US 1,094 1,043 5.0% 5.0% - 2,140 2,045 4.7% 4.7% -
Intl 1,559 1,512 3.1% 0.5% 2.6% 3,024 2,906 4.1% (0.3)% 4.4%
WW 2,653 2,555 3.9% 2.3% 1.6% 5,164 4,951 4.3% 1.8% 2.5%
ADVANCED
US 499 477 4.7% 4.7% - 976 934 4.5% 4.5% -
Intl 691 687 0.5% (1.9)% 2.4% 1,337 1,303 2.6% (1.4)% 4.0%
WW 1,189 1,164 2.2% 0.8% 1.4% 2,312 2,237 3.4% 1.0% 2.4%
GENERAL
US 596 567 5.2% 5.2% - 1,165 1,111 4.8% 4.8% -
Intl 868 825 5.3% 2.5% 2.8% 1,687 1,603 5.2% 0.7% 4.5%
WW 1,464 1,391 5.2% 3.6% 1.6% 2,852 2,714 5.1% 2.4% 2.7%
See footnotes at end of schedule
% Change	% Change

-- 17 of 22 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
VISION
US 565	$ 557 1.4% 1.4% - 1,144	$ 1,123 1.9% 1.9% -
Intl 887 813 9.1% 8.5% 0.6% 1,672 1,526 9.6% 6.7% 2.9%
WW 1,451 1,369 6.0% 5.6% 0.4% 2,816 2,648 6.3% 4.6% 1.7%
CONTACT LENSES / OTHER
US 445 429 3.6% 3.6% - 913 881 3.7% 3.7% -
Intl 580 536 8.1% 7.9% 0.2% 1,081 1,003 7.7% 5.0% 2.7%
WW 1,025 965 6.1% 6.0% 0.1% 1,994 1,884 5.8% 4.4% 1.4%
SURGICAL
US 120 128 (6.0)% (6.0)% - 231 242 (4.5)% (4.5)% -
Intl 306 277 10.9% 9.6% 1.3% 591 523 13.1% 9.8% 3.3%
WW 426 403 5.6% 4.7% 0.9% 822 764 7.5% 5.3% 2.2%
ORTHOPAEDICS
US 1,470 1,420 3.5% 3.5% - 2,905 2,804 3.6% 3.6% -
Intl 948 885 7.2% 5.3% 1.9% 1,896 1,742 8.9% 3.9% 5.0%
WW 2,418 2,305 4.9% 4.2% 0.7% 4,801 4,546 5.6% 3.7% 1.9%
HIPS
US 283 271 4.6% 4.6% - 560 534 4.9% 4.9% -
Intl 158 150 5.5% 3.0% 2.5% 317 296 7.2% 1.7% 5.5%
WW 441 421 4.9% 4.0% 0.9% 877 830 5.7% 3.8% 1.9%
KNEES
US 228 226 1.1% 1.1% - 467 457 2.2% 2.2% -
Intl 182 164 11.4% 10.3% 1.1% 363 322 13.0% 8.4% 4.6%
WW 410 389 5.5% 5.0% 0.5% 830 778 6.7% 4.8% 1.9%
TRAUMA
US 536 501 6.7% 6.7% - 1,068 1,003 6.4% 6.4% -
Intl 291 267 9.2% 7.4% 1.8% 592 537 10.3% 5.2% 5.1%
WW 827 768 7.6% 6.9% 0.7% 1,660 1,540 7.8% 6.0% 1.8%
SPINE, SPORTS & OTHER
US 423 422 0.2% 0.2% - 810 810 0.0% 0.0% -
Intl 317 305 4.0% 1.9% 2.1% 624 588 6.1% 1.3% 4.8%
WW 740 727 1.8% 0.9% 0.9% 1,434 1,398 2.6% 0.6% 2.0%
TOTAL MEDTECH
US 4,554 4,383 3.9% 3.9% - 9,013 8,596 4.8% 4.8% -
Intl 4,372 4,158 5.2% 3.2% 2.0% 8,549 7,965 7.3% 3.2% 4.1%
WW 8,926	$ 8,541 4.5% 3.6% 0.9% 17,562	$ 16,561 6.0% 4.1% 1.9%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change	% Change

-- 18 of 22 --

Innovative Medicine
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 4,296	$ (764) (18) (9) 3,505
Selling, marketing and admin expenses 3,130 3,130
Research and development expense 2,875 2,875
Other segment items (166) 91 (182) (54) 227 (84)
Adjusted Income Before Tax by Segment 6,249 764 (91) 200 63 (227) - - 6,958
MedTech
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 3,737	$ (481) (17) (3) 3,236
Selling, marketing and admin expenses 3,069 (17) 3,052
Research and development expense 778 (2) 776
Other segment items 165 76 (59) (37) (14) (236) (105)
Adjusted Income Before Tax by Segment 1,177 481 (76) 76 37 14 258 - 1,967
Expenses not allocated to segments
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 18	$ 18
Selling, marketing and admin expenses 233 233
Research and development expense - -
Other segment items 428 (434) 20 14
Adjusted Income Before Tax by Segment (679) - 434 - (20) - - - (265)
Johnson & Johnson Consolidated
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 8,051	$ (1,245) (35) (9) (3) 6,759
Selling, marketing and admin expenses 6,432 (17) 6,415
Research and development expense 3,653 (2) 3,651
Other (Income) / Expense 331 (267) (207) (71) 213 (236) (237)
In-process research and development impairments - -
Interest (Income)/Expense 62 62
Restructuring 34 (34) -
Adjusted Income Before Tax 6,747 1,245 267 276 80 (213) 258 - 8,660
Provision for taxes on income 1,213 239 59 54 23 (50) 43 (2) 1,579
Net Earnings 5,534	$ 1,006 208 222 57 (163) 215 2 7,081
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 19 of 22 --

Innovative Medicine
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 3,978	$ (785) (13) 3,180
Selling, marketing and admin expenses 2,789 2,789
Research and development expense 2,869 2,869
Other segment items 14 69 (207) 8 (13) (129)
Adjusted Income Before Tax by Segment 5,552 785 (69) - 220 (8) - 13 6,493
MedTech
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 3,638	$ (482) (15) 1 3,142
Selling, marketing and admin expenses 2,862 2,862
Research and development expense 647 43 690
Other segment items 190 (83) (64) (53) (29) (14) (53)
Adjusted Income Before Tax by Segment 1,204 482 83 79 9 29 - 14 1,900
Expenses not allocated to segments
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 12	$ 12
Selling, marketing and admin expenses 238 238
Research and development expense - -
Other segment items 15 (43) (17) (45)
Adjusted Income Before Tax by Segment (265) - 43 - 17 - - - (205)
Johnson & Johnson Consolidated
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 7,628	$ (1,267) (15) (12) 6,334
Selling, marketing and admin expenses 5,889 5,889
Research and development expense 3,516 43 3,559
Other (Income) / Expense 107 (57) (277) (21) (27) (275)
In-process research and development impairments - -
Interest (Income)/Expense 48 48
Restructuring 64 (64) -
Adjusted Income Before Tax 6,491 1,267 57 79 246 21 - 27 8,188
Provision for taxes on income 954 222 9 13 72 5 214 - 1,489
Net Earnings 5,537	$ 1,045 48 66 174 16 (214) 27 6,699
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 20 of 22 --

Year to Date
Innovative Medicine
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 8,686	$ (1,527) (18) (19) 7,122
Selling, marketing and admin expenses 6,048 6,048
Research and development expense 5,688 5,688
Other segment items (178) 51 (182) (100) 282 (127)
Adjusted Income Before Tax by Segment 11,566 1,527 (51) - 200 119 (282) - - 13,079
MedTech
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 7,438	$ (965) (42) (3) 6,428
Selling, marketing and admin expenses 5,975 (17) 5,958
Research and development expense 1,492 (2) 1,490
Other segment items 241 117 (36) (96) (64) (10) (355) (203)
Adjusted Income Before Tax by Segment 2,416 965 (117) 36 138 64 10 377 - 3,889
Expenses not allocated to segments
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 33	$ 33
Selling, marketing and admin expenses 443 443
Research and development expense - -
Other segment items 769 (765) 7 11
Adjusted Income Before Tax by Segment (1,245) - 765 - - (7) - - - (487)
Johnson & Johnson Consolidated
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 16,157	$ (2,492) (60) (19) (3) 13,583
Selling, marketing and admin expenses 12,466 (17) 12,449
Research and development expense 7,180 (2) 7,178
Other (Income) / Expense 625 (597) (212) (157) 272 (355) (424)
In-process research and development impairments 36 (36) -
Interest (Income)/Expense 105 105
Restructuring 66 (66) -
Adjusted Income Before Tax 12,737 2,492 597 36 338 176 (272) 377 - 16,481
Provision for taxes on income 1,968 479 131 8 124 45 (63) 68 26 2,786
Net Earnings 10,769	$ 2,013 466 28 214 131 (209) 309 (26) 13,695
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 21 of 22 --

Year to Date
Innovative Medicine
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 7,998	$ (1,434) (13) 6,551
Selling, marketing and admin expenses 5,050 5,050
Research and development expense 5,417 5,417
Other segment items (152) - 69 (227) (10) (13) (333)
Adjusted Income Before Tax by Segment 10,762 1,434 (69) - 240 10 - 13 12,390
MedTech
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 6,964	$ (953) (23) (51) 5,937
Selling, marketing and admin expenses 5,518 5,518
Research and development expense 1,324 37 1,361
Other segment items 130 (83) (111) (107) (50) (14) (235)
Adjusted Income Before Tax by Segment 2,625 953 83 134 121 50 - 14 3,980
Expenses not allocated to segments
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 23	$ 23
Selling, marketing and admin expenses 433 433
Research and development expense - -
Other segment items (7,191) 6,923 (17) (285)
Adjusted Income Before Tax by Segment 6,735 - (6,923) - 17 - - - (171)
Johnson & Johnson Consolidated
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 14,985	$ (2,387) (23) (64) 12,511
Selling, marketing and admin expenses 11,001 11,001
Research and development expense 6,741 37 6,778
Other (Income) / Expense (7,214) 6,909 (30) (351) (60) (27) (773)
In-process research and development impairments - -
Interest (Income)/Expense (80) (80)
Restructuring 81 (81) -
Adjusted Income Before Tax 20,122 2,387 (6,909) 134 378 60 - 27 16,199
Provision for taxes on income 3,586 410 (1,544) 24 102 14 202 2,794
Net Earnings 16,536	$ 1,977 (5,365) 110 276 46 (202) 27 13,405
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 22 of 22 --